Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elacytarabine versus investigator's choice chemotherapy for relapsed or refractory acute myeloid leukemia
ACTRN12611000474954Phase 3Recruiting
- Sponsor
- Clavis Pharma
- Start
- Aug 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of elacytarabine in acute myeloid leukemia (AML), sponsored by Clavis Pharma. Primary endpoint: Overall survival. Started Aug 2010; status: recruiting.
02
Drugs
elacytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12611000474954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000474954.